Context The present summary of the European Association of Urology (EAU) guidelines is
based on the latest guidelines on male sexual health published in March 2021, with a last …

Background Clinical research affecting how doctors practice medicine is increasingly
sponsored by companies that make drugs and medical devices. Previous systematic …

Background The cardiovascular safety of testosterone-replacement therapy in middle-aged
and older men with hypogonadism has not been determined. Methods In a multicenter …

Purpose: There has been a marked increase in testosterone prescriptions in the past
decade resulting in a growing need to give practicing clinicians proper guidance on the …

Background Serum testosterone concentrations decrease as men age, but benefits of
raising testosterone levels in older men have not been established. Methods We assigned …

Background Testosterone is the standard treatment for male hypogonadism, but there is
uncertainty about its cardiovascular safety due to inconsistent findings. We aimed to provide …

Testosterone is a key hormone in the pathology of metabolic diseases such as obesity. Low
testosterone levels are associated with increased fat mass (particularly central adiposity) …

Testosterone (T) is the principal male sex hormone. As men age, T levels typically fall.
Symptoms of low T include decreased libido, vasomotor instability, and decreased bone …

The hypothalamic–pituitary–gonadal axis is of relevance in many processes related to the
development, maturation and ageing of the male. Through this axis, a cascade of …

Male hypogonadism (MH) is a common endocrine disorder. However, uncertainties and
variations in its diagnosis and management exist. There are several current guidelines on …